Checkpoint Therapeutics (NASDAQ:CKPT) Upgraded to “Buy” by ValuEngine

ValuEngine upgraded shares of Checkpoint Therapeutics (NASDAQ:CKPT) from a hold rating to a buy rating in a report published on Thursday, ValuEngine reports.

A number of other research firms also recently commented on CKPT. HC Wainwright increased their price objective on shares of Checkpoint Therapeutics from $11.00 to $15.00 and gave the company a buy rating in a report on Wednesday, May 1st. Lake Street Capital started coverage on shares of Checkpoint Therapeutics in a report on Wednesday, May 29th. They issued a buy rating for the company.

Checkpoint Therapeutics stock traded up $0.12 during midday trading on Thursday, reaching $2.41. The company had a trading volume of 20,649 shares, compared to its average volume of 62,227. Checkpoint Therapeutics has a 12-month low of $1.50 and a 12-month high of $5.20. The business has a fifty day moving average of $3.22.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.18) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.09. The company had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.96 million. Checkpoint Therapeutics had a negative net margin of 952.83% and a negative return on equity of 211.99%. On average, equities analysts anticipate that Checkpoint Therapeutics will post -0.64 EPS for the current fiscal year.

A hedge fund recently bought a new stake in Checkpoint Therapeutics stock. Park Avenue Securities LLC acquired a new stake in Checkpoint Therapeutics Inc (NASDAQ:CKPT) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 66,593 shares of the company’s stock, valued at approximately $199,000. Park Avenue Securities LLC owned about 0.19% of Checkpoint Therapeutics at the end of the most recent quarter. 8.52% of the stock is owned by institutional investors and hedge funds.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in the phase 1/2 clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and CK-301, a programmed death ligand-1 (PD-L1), which is in phase I clinical trial in patients with selected recurrent or metastatic cancers.

See Also: What is the return on assets formula?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with's FREE daily email newsletter.